Men who undergo hormone therapy for prostate tumours have a bigger chance of developing intestinal cancer, according to a study.
Researchers at the cantonal hospital of St Gallen examined the files of 108,000 men suffering from prostate tumours in the United States from 1993 to 2002.
They concluded that patients following hormone therapy to fight the tumour had a greater risk of developing intestinal cancer.
Out of 1,000 men, 4.4 patients taking hormones developed the illness within a year compared with only 3.7 patients who weren’t taking them.
Testicular ablation, an outdated method of treating prostate cancer, is even worse, according to the study, as 6.3 patients out of 1,000 develop intestinal cancer after an ablation.
All rights reserved. The content of the website by swissinfo.ch is copyrighted. It is intended for private use only. Any other use of the website content beyond the use stipulated above, particularly the distribution, modification, transmission, storage and copying requires prior written consent of swissinfo.ch. Should you be interested in any such use of the website content, please contact us via contact@swissinfo.ch.
As regards the use for private purposes, it is only permitted to use a hyperlink to specific content, and to place it on your own website or a website of third parties. The swissinfo.ch website content may only be embedded in an ad-free environment without any modifications. Specifically applying to all software, folders, data and their content provided for download by the swissinfo.ch website, a basic, non-exclusive and non-transferable license is granted that is restricted to the one-time downloading and saving of said data on private devices. All other rights remain the property of swissinfo.ch. In particular, any sale or commercial use of these data is prohibited.
